Fang Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fang Wu has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Chuyue Zhong
Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China; Central Laboratory, The First Affiliated Hospital of Wenzhou Medical University
3 shared publicationsJiacheng Li
Department of Gastroenterology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University
3 shared publicationsQiwen Chen
Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China; Central Laboratory, The First Affiliated Hospital of Wenzhou Medical University
3 shared publicationsRui Zhao
Fourth Department of Liver Disease, Beijing You’an Hospital, Capital Medical University
3 shared publications- Xin-Li Mao
Department of Gastroenterology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Taizhou 317000, China
3 shared publications Yuxin Chen
Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China; Central Laboratory, The First Affiliated Hospital of Wenzhou Medical University
3 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1967353
Beyond inflammation: exploring CAR-based cell therapy for fibrostenosing Crohn’s disease
Fibrostenosing Crohn’s disease (FSCD) is driven by chronic inflammation, fibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling. Current management includes medical treatment to control inflammation, endoscopic interventions, and surgery to relieve clinically significant strictures. Chimeric antigen receptor (CAR)-based cell therapy represents an emerging research direction that may enable targeted intervention against selected cell populations implicated in fibrogenesis. Unlike approaches focused primarily on inflammatory control, CAR-based strategies can be engineered to recognize selected cellular populations, offering a potential means of directly targeting cells involved in fibrotic remodeling or modulating the local profibrotic microenvironment. By integrating insights from intestinal pathobiology with evidence from other fibrotic settings, we assess candidate cellular targets, therapeutic modalities, and CAR-cell platforms, and consider how these choices should be aligned with lesion accessibility, disease stage, therapeutic objectives, and safety requirements. We further discuss the translational challenges of CAR-based approaches for FSCD.
- 30 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1967353
Open AccessBeyond inflammation: exploring CAR-based cell therapy for fibrostenosing Crohn’s disease
Fibrostenosing Crohn’s disease (FSCD) is driven by chronic inflammation, fibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling. Current management includes medical treatment to control inflammation, endoscopic interventions, and surgery to relieve clinically significant strictures. Chimeric antigen receptor (CAR)-based cell therapy represents an emerging research direction that may enable targeted intervention against selected cell populations implicated in fibrogenesis. Unlike approaches focused primarily on inflammatory control, CAR-based strategies can be engineered to recognize selected cellular populations, offering a potential means of directly targeting cells involved in fibrotic remodeling or modulating the local profibrotic microenvironment. By integrating insights from intestinal pathobiology with evidence from other fibrotic settings, we assess candidate cellular targets, therapeutic modalities, and CAR-cell platforms, and consider how these choices should be aligned with lesion accessibility, disease stage, therapeutic objectives, and safety requirements. We further discuss the translational challenges of CAR-based approaches for FSCD.
- 31 July 2026
- Published by Elsevier in Phytomedicine
- Vol. 160, 158641
Eleutheroside E alleviates ulcerative colitis by suppressing Th17 immune response via the MAPK signaling pathway and remodeling gut microbiota
- 31 July 2026
- Published by Elsevier in Phytomedicine
- Vol. 160, 158641
Eleutheroside E alleviates ulcerative colitis by suppressing Th17 immune response via the MAPK signaling pathway and remodeling gut microbiota
- 15 July 2026
- Published by Elsevier in Phytomedicine
- p. 158555
Corrigendum to "Xanthoxylin alleviates dextran sulfate sodium (DSS)-induced colitis by targeting macrophage infiltration via the tumor necrosis factor (TNF)/nuclear factor-kappa B (NF-κB) signaling pathway" [Phytomedicine 153:157971 (2026) PMID: 41720014].
- 15 July 2026
- Published by Elsevier in Phytomedicine
- p. 158555
Corrigendum to "Xanthoxylin alleviates dextran sulfate sodium (DSS)-induced colitis by targeting macrophage infiltration via the tumor necrosis factor (TNF)/nuclear factor-kappa B (NF-κB) signaling pathway" [Phytomedicine 153:157971 (2026) PMID: 41720014].
- Open Access
- 15 December 2025
- Published by Wiley in Advanced Science
- Vol. 13 (13) , e09541
Western Diet Inhibits FUT7‐Mediated Treg Intestinal Homing to Disrupt the Homeostasis of Intestinal Epithelial Cells in Crohn's Disease
The Western diet (WD) is a potential risk factor for developing Crohn's disease (CD), characterized by disordered homeostasis of intestinal epithelial cells (IECs). However, how WD disrupts the IEC homeostasis remains unclear. Here, it is shown that WD disrupts the IEC homeostasis through inhibiting Fut7‐mediated Treg intestinal homing to weaken Treg and IEC signaling crosstalk. In this study, it is found that WD disrupted the IEC barrier, downregulated Fut7 expression in Tregs, and decreased colonic Tregs. The combined analyses of single‐cell RNA‐sequencing and spatial transcriptomics revealed that WD weakened the intestinal homing ability of Tregs and the signaling crosstalk between Tregs and IECs. Furthermore, Treg‐specific Fut7 knockout decreased colonic Tregs and aggravated the severity of colitis and IEC barrier disruption in the 2,4,6‐trinitrobenzenesulfonic acid‐induced mouse CD model, while upregulation of Fut7 in Tregs alleviated their severity. On top of this model, transfer of Tregs in vivo ameliorated colitis and IEC barrier disruption in the naive CD4 + T cell transfer model, but Fut7‐knockdown Tregs cannot do so. In addition, it is found that FUT7 expression in Tregs is downregulated in patients with active CD. Thus, these findings offer a novel insight into the pathogenesis of CD.
- 15 December 2025
- Published by Wiley in Advanced Science
- Vol. 13 (13) , e09541
Open AccessWestern Diet Inhibits FUT7‐Mediated Treg Intestinal Homing to Disrupt the Homeostasis of Intestinal Epithelial Cells in Crohn's Disease
The Western diet (WD) is a potential risk factor for developing Crohn's disease (CD), characterized by disordered homeostasis of intestinal epithelial cells (IECs). However, how WD disrupts the IEC homeostasis remains unclear. Here, it is shown that WD disrupts the IEC homeostasis through inhibiting Fut7‐mediated Treg intestinal homing to weaken Treg and IEC signaling crosstalk. In this study, it is found that WD disrupted the IEC barrier, downregulated Fut7 expression in Tregs, and decreased colonic Tregs. The combined analyses of single‐cell RNA‐sequencing and spatial transcriptomics revealed that WD weakened the intestinal homing ability of Tregs and the signaling crosstalk between Tregs and IECs. Furthermore, Treg‐specific Fut7 knockout decreased colonic Tregs and aggravated the severity of colitis and IEC barrier disruption in the 2,4,6‐trinitrobenzenesulfonic acid‐induced mouse CD model, while upregulation of Fut7 in Tregs alleviated their severity. On top of this model, transfer of Tregs in vivo ameliorated colitis and IEC barrier disruption in the naive CD4 + T cell transfer model, but Fut7‐knockdown Tregs cannot do so. In addition, it is found that FUT7 expression in Tregs is downregulated in patients with active CD. Thus, these findings offer a novel insight into the pathogenesis of CD.